Yahoo Finance 4 Pharma Stocks Gaining Speed on Monday (12/31/18)
CORAL GABLES, FL/ ACCESSWIRE / December 31,2018 / With the new year only moments away, companies in the pharmaceutical industry are working hard to create new methods and approaches for treating patients with innumerable diseases and ailments. The fact of the matter is consumers, across all sectors, are more demanding nowadays than previous generations. Companies fully recognize how crucial it is to meet both the needs and expectations of patients through the creation of products and services tailored to the specific qualifications of each patient. From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Rite Aid Corporation (RAD), Adamis Pharmaceuticals Corp (ADMP), and Synergy Pharmaceuticals Inc (SGYP) are 4 pharma stocks heating up on Monday.
Premier Health Group (PHGRF) (PHGI), a company dominating the telehealth sector of the healthcare industry, has enjoyed a strong month of bullish trading, with Company shares soaring well above the 30% mark in a 30-day period. Earlier this month, as part of its overarching strategy to cover major verticals associated with primary care, the Company signed into a binding Letter of Intent (LOI) agreement to acquire a Vancouver-based pharmacy. According to details regarding the agreement, the Company expects the deal to close in or about Q1-19. Currently, Premier Health Group (PHGRF) (PHGI) supports an ecosystem of over 100,000 active patients and has plans in the works to rapidly increase these numbers on both a domestic, as well as international scale.
"We are excited for this opportunity to acquire our first pharmacy, and thereafter being able to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients. In doing so, the pharmacist will play an integral role in our team-basedpatient centric model," said Dr. Essam Hamza, CEO of Premier. "Premier has engaged with patients, pharmacies and technology providers to not only introduce pharmacy services as a component of our comprehensive telemedicineapp, but also to explore and implement efficienciesin fill and fulfillment."
For More Information On Premier Health Group, Click Here
Rite Aid Corporation (RAD) announced earlier this month that it had entered intonew senior secured credit agreement, consisting of a $2.7 billion senior secured asset-based revolving credit facility and a $450 million ''first in, last out'' senior secured term loan facility.
According to the press release issued at the time of the announcement, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Wells Fargo Bank, National Association, Citigroup Global Markets Inc., BMO Harris Bank, N.A., Capital One, National Association, Fifth Third Bank, ING Capital LLC, MUFG Union Bank, N.A., PNC Capital Markets LLC and SunTrust Robinson Humphrey, Inc., acted as joint lead arrangers and joint book runners for the new facilities. Bank of America, N.A. is acting as administrative agent and collateral agent under the new credit facilities.
For More Information On Rite Aid Corporation, Click Here
Adamis Pharmaceuticals Corporation (ADMP) saw itself in headlines at the tail-end of last week, when the Company announced their recent submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its fast-dissolving sublingualtaladafil tablet. According to the report, the new drug used for treating erectile dysfunction, pulmonary hypertensionand benign prostatic hyperplasia.
In a press release regarding the matter, Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis, stated: "The filing for the NDA for our tadalafil tablet represents an important milestone for our company. We are very pleased with the progress we have made with our tadalafil product candidate which we believe is well-positioned to compete in the large, multi-billion-dollar erectile dysfunction market. We look forward to working through the review process with the FDA and hope to bring this low-cost therapeutic alternative to the market."
For More Information on Adamis Pharmaceuticals Corporation, Click Here
Synergy Pharmaceuticals, Inc (SGYP) a biopharmaceutical company that is largely focused on developing originative gastrointestinal therapies, announced earlier this month that it had entered into an agreement with Bausch Health Companies Inc. through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE®,dolcanatide and related intellectual property, for approximately $200 million in cash.
Said Troy Hamilton, Chief Executive Officer of Synergy: "We have worked diligently to serve our patients, health care professionalsand other stakeholders by bringing TRULANCE® to market and developing other GI therapies to address previously unmet needs. Unfortunately, we have now reached a point where our financial challenges are preventing us from taking this important work to the next level."
For More Information On Synergy Pharmaceuticals, Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com